Bone marrow mesenchymal stem cells protect against bleomycin-induced pulmonary fibrosis in rat by activating Nrf2 signaling

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 7, 2015, Pages 7752-7761

  Ni, Shirong ^a,b   Wang, Dexuan ^b   Qiu, Xiaoxiao ^b   Pang, Lingxia ^b   Song, Zhangjuan ^b   Guo, Kunyuan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antioxidant enzymes; BMSCs; Nrf2; Oxidative stress; Pulmonary fibrosis

Indexed keywords

BLEOMYCIN; COLLAGEN; HYDROXYPROLINE; MALONALDEHYDE; PROTECTIVE AGENT; TRANSCRIPTION FACTOR NRF2;

ANIMAL; BONE MARROW CELL; CHEMICALLY INDUCED; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG; LUNG FIBROSIS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BLEOMYCIN; BONE MARROW CELLS; COLLAGEN; GENE EXPRESSION REGULATION; HUMANS; HYDROXYPROLINE; LUNG; MALONDIALDEHYDE; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PROTECTIVE AGENTS; PULMONARY FIBROSIS; RATS; SIGNAL TRANSDUCTION;

EID: 85012994401     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP 3rd. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004; 64: 405-430.
2. Kim DS. Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res 2013; 14: 86.
3. Raghu G, Chang J. Idiopathic pulmonary fibrosis: current trends in management. Clin Chest Med 2004; 25: 621-636.
4. Maher TM. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012; 33: 69-83.
5. Antoniou KM, Margaritopoulos GA, Siafakas NM. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev 2013; 22: 281-291.
6. Rahman I, Skwarska E, Henry M, Davis M, O'Connor CM, FitzGerald MX, Greening A, MacNee W. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med 1999; 27: 60-68.
7. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxi-dative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005; 172: 417-422.
8. Daniil ZD, Papageorgiou E, Koutsokera A, Kostikas K, Kiropoulos T, Papaioannou AI, Gourgoulianis KI. Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2008; 21: 26-31.
9. Yang J, Song TB, Zhao ZH, Qiu SD, Hu XD, Chang L. Vasoactive intestinal peptide protects against ischemic brain damage induced by focal cerebral ischemia in rats. Brain Res 2011; 1398: 94-101.
10. Punithavathi D, Venkatesan N, Babu M. Cur-cumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol 2000; 131: 169-172.
11. Pekovic-Vaughan V, Gibbs J, Yoshitane H, Yang N, Pathiranage D, Guo B, Sagami A, Taguchi K, Bechtold D, Loudon A, Yamamoto M, Chan J, van der Horst GT, Fukada Y, Meng QJ. The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis. Genes Dev 2014; 28: 548-560.
12. Zucker SN, Fink EE, Bagati A, Mannava S, Bianchi-Smiraglia A, Bogner PN, Wawrzyniak JA, Foley C, Leonova KI, Grimm MJ, Moparthy K, Ionov Y, Wang J, Liu S, Sexton S, Kandel ES, Bakin AV, Zhang Y, Kaminski N, Segal BH, Nikiforov MA. Nrf2 amplifies oxidative stress via induction of Klf9. Mol Cell 2014; 53: 916-928.
13. Artaud-Macari E, Goven D, Brayer S, Hamimi A, Besnard V, Marchal-Somme J, Ali ZE, Crestani B, Kerdine-Römer S, Boutten A, Bonay M. Nuclear factor erythroid 2-related factor 2 nuclear translocation induces myofibroblastic dedifferentiation in idiopathic pulmonary fibrosis. Antioxid Redox Signal 2013; 18: 66-79.
14. White ES, Lazar MH, Thannickal VJ. Patho-genetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J Pathol 2003; 201: 343-354.
15. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29: 371-387.
16. Azambuja E, Fleck JF, Batista RG, Menna Barreto SS. Bleomycin lung toxicity: who are the patients with increased risk? Pulm Phar-macol Ther 2005; 18: 363-366.
17. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008; 40: 362-382.
18. Wan YY, Tian GY, Guo HS, Kang YM, Yao ZH, Li XL, Liu QH, Lin DJ. Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats. Respir Res 2013; 14: 56.
19. Chaudhary NI, Schnapp A, Park JE. Pharma-cologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006; 173: 769-776.
20. Mouratis MA, Aidinis V. Modeling pulmonary fibrosis with bleomycin. Curr Opin Pulm Med 2011; 17: 355-361.
21. Cheresh P, Kim SJ, Tulasiram S, Kamp DW. Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta 2013; 1832: 1028-1040.
22. Fubini B, Hubbard A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic Biol Med 2003; 34: 1507-1516.
23. Mukaigasa K, Nguyen LT, Li L, Nakajima H, Yamamoto M, Kobayashi M. Genetic evidence of an evolutionarily conserved role for Nrf2 in the protection against oxidative stress. Mol Cell Biol 2012; 32: 4455-4461.
24. Itoh K, Tong KI, Yamamoto M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med 2004; 36: 1208-1213.
25. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 2005; 7: 385-394.
26. Bardag-Gorce F, Oliva J, Lin A, Li J, French BA, French SW. Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease. Exp Mol Pathol 2011; 90: 123-130.
27. Farombi EO, Shrotriya S, Na HK, Kim SH, Surh YJ. Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. Food Chem Toxicol 2008; 46: 1279-1287.
28. Mulcahy RT, Wartman MA, Bailey HH, Gipp JJ. Constitutive and beta-naphthoflavone-induced expression of the human gamma-glutamylcysteine synthetase heavy subunit gene is regulated by a distal antioxidant response element/TRE sequence. J Biol Chem 1997; 272: 7445-7454.
29. Jeong WS, Jun M, Kong AN. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal 2006; 8: 99-106.
30. Mann GE, Niehueser-Saran J, Watson A, Gao L, Ishii T, de Winter P, Siow RC. Nrf2/ARE regulated antioxidant gene expression in endothelial and smooth muscle cells in oxidative stress: implications for atherosclerosis and preeclampsia. Sheng Li Xue Bao 2007; 59: 117-127.
31. Adamali HI, Maher TM. Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther 2012; 6: 261-272.
32. Whelan TP. Lung transplantation for interstitial lung disease. Clin Chest Med 2012; 33: 179-189.
33. McShane PJ, Garrity ER Jr. Minimization of immunosuppression after lung transplantation: current trends. Transpl Int 2009; 22: 90-95.
34. Cargnoni A, Gibelli L, Tosini A, Signoroni PB, Nassuato C, Arienti D, Lombardi G, Albertini A, Wengler GS, Parolini O. Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. Cell Transplant 2009; 18: 405-422.
35. Chang YS, Oh W, Choi SJ, Sung DK, Kim SY, Choi EY, Kang S, Jin HJ, Yang YS, Park WS. Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats. Cell Transplant 2009; 18: 869-886.